natgillin/translations-raw huggingface dataset:
Unit according to claim 5 or 6, wherein said collars and said spacer elements are made in one piece with each other to form a single structure (45) of elastically deformable material. 
Jedinica u skladu s patentnim zahtjevom 5 ili 6, naznačena time što su navedene obujmice i navedeni razmačni elementi načinjeni međusobno jednodijelno kako bi tvorili pojedinačnu strukturu (45) od materijala koji se može elastično deformirati.
Unit according to claim 11, wherein said interposition structure (44) is a continuous structure, which extends for the entire perimeter of the cylinder in transverse cross-section, or a discontinuous structure, consisting of a plurality of elements distributed along the perimetric extension of the cylinder in transverse cross section. 
Jedinica u skladu s patentnim zahtjevom 11, naznačena time što je navedena međustruktura (44) kontinuirana struktura, koja se pruža po cijelom obodu boce u poprečnom presjeku, ili diskontinuirana struktura, koja se sastoji od više elemenata raspodijeljenih po obodu boce u poprečnom presjeku.
Unit according to claim 11 or 12, wherein the elastically deformable material which forms said interposition structure (44) provides a coefficient of friction with the cylinder (20) sufficiently low as not to hinder the axial translations of the cylinder relative to the collar (42). 
Jedinica u skladu s patentnim zahtjevom 11 ili 12, naznačena time što materijal koji se može elastično deformirati, koji tvori navedenu međustrukturu (44), pruža koeficijent trenja s bocom (20) dovoljno nizak da ne ometa aksijalno translatorno pomicanje boca u odnosu na obujmicu (42).
Marine vessel according to claim 15, wherein said one or more multiple containment units of compressed gas are installed in a hold or on a deck of said marine vessel. 
Pomorsko plovilo u skladu s patentnim zahtjevom 15, naznačeno time što su navedena jedna ili više višestrukih jedinica za spremanje stlačenog plina ugrađene u skladištu ili na palubi navedenog pomorskog plovila.
A pharmaceutical composition for use in a method of treating a subject having cancer, wherein said method comprises orally administering said pharmaceutical composition once per day, and wherein said pharmaceutical composition comprises a therapeutically effective amount of 5-azacytidine and is an immediate release composition. 
Farmaceutski sastav za upotrebu u postupku liječenja subjekta koji ima karcinom, gdje spomenuti postupak obuhvaća oralnu primjenu spomenutog farmaceutskog sastava jednom dnevno, i gdje spomenuti farmaceutski sastav obuhvaća terapeutski efikasnu količinu 5-azacitidina i sastav je s trenutnim oslobađanjem.
A pharmaceutical composition for use according to claim 1, wherein said method comprises administering daily to the subject said pharmaceutical composition for 7 or more days. 
Farmaceutski sastav za upotrebu prema zahtjevu 1, gdje spomenuti postupak obuhvaća dnevno davanje subjektu spomenutog farmaceutskog sastava tijekom 7 ili više dana.
The pharmaceutical composition for use according to claim 1 or claim 2, wherein said method further comprises administering an additional therapeutic agent. 
Farmaceutski sastav za upotrebu prema zahtjevu 1 ili zahtjevu 2, gdje spomenuti postupak dalje obuhvaća davanje dodatnog terapeutskog sredstva.
The pharmaceutical composition for use according to any one of claims 1 to 3, wherein the cancer is myelodysplastic syndrome, acute myelogenous leukemia, non-small-cell lung cancer, ovarian cancer, pancreatic cancer or colorectal cancer. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 3, gdje je karcinom mijelodisplastični sindrom, akutna mijeloična leukemija, karcinom pluća nemalih stanica, karcinom jajnika, karcinom gušterače ili kolorektalni karcinom.
The pharmaceutical composition for use according to any one of claims 1 to 4, wherein the amount of 5-azacytidine is about 40 mg, about 400 mg, or about 1000 mg. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 4, gdje je količina 5-azacitidina oko 40 mg, oko 400 mg, ili oko 1000 mg.
The pharmaceutical composition for use according to any one of claims 1 to 5, wherein the composition is non-enteric coated. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 5, gdje sastav nije gastrorezistentno obložena.
The pharmaceutical composition for use according to any one of claims 1 to 3, wherein the composition is a single unit dosage form. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 6, gdje je sastavu pojedinačnom doznom obliku.
The pharmaceutical composition for use according to any one of claims 1 to 7, wherein the composition is a tablet or capsule. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 7, gdje je sastav tableta ili kapsula.
The pharmaceutical composition for use according to any one of claims 1 to 8, wherein the composition further comprises an excipient selected from mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 8, gdje sastav dalje sadrži pomoćnu tvar izabranu između manitola, mikrokristalne celuloze, krospovidona i magnezijeva stearata.
The pharmaceutical composition for use according to any one of claims 1 to 9, wherein the composition further comprises a permeation enhancer. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 9, gdje sastav dalje obuhvaća pojačivač permeacije.
The pharmaceutical composition for use according to any one of claims 1 to 8, wherein the composition achieves an area-under-the-curve value of at least about 200 ng-hr/mL or at least about 400 ng-hr/mL following oral administration, or wherein the composition achieves a maximum plasma concentration of at least about 100 ng/mL or at least about 200 ng/mL following oral administration, or wherein the composition achieves a time to maximum plasma concentration of less than about 60 minutes, less than about 90 minutes, or less than about 180 minutes following oral administration to the subject. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 12, gdje sastav postiže vrijednost površine ispod krivulje od bar oko 200 ng-hr/mL ili bar oko 400 ng-hr/mL poslije oralnog uzimanja, ili gdje sastav postiže maksimalnu koncentraciju u plazmi od bar oko 100 ng/mL ili bar oko 200 ng/mL poslije oralnog uzimanja, ili gdje sastav postiže vrijeme maksimalne koncentracije u plazmi manje od oko 60 minuta, manje od oko 90 minuta, ili manje od oko 180 minuta poslije oralnog uzimanja subjekta.
The composition of any one of claims 1 to 9, wherein the subject is a human. 
Sastav prema bilo kojem od zahtjeva 1 do 13, gdje je subjekt čovjek.
-H; or the other is C1-C6 alkyl that is optionally substituted with: 
H; ili je drugi C1-C6 alkil koji je po izboru supstituiran s:
OH, methoxy, ethoxy, -OCH(CH3)2, -O(CH2)2CH3, phenyl, furanyl, - O(CH2)2OH, phenoxy, methylthio, -F, -N(CH3)2, cyano, pyridinyloxy, fluorophenoxy, isochromanyl, phenol, benzylamino, -NHCH3, oxo-, amino, carboxyl, 7-member spiroaminyl, a three to six member cycloalkyl, saturated or unsaturated and optionally including one or more heteroatoms selected from O and N, and optionally substituted at one or more C or N atoms by methyl, cyano, fluoro, methylamino, or trifluoromethyl; or the other is 
OH, metoksi, etoksi, -OCH(CH3)2, -O(CH2)2CH3, fenilom, furanilom, - O(CH2)2OH, fenoksi, metiltio, -F, -N(CH3)2, cijano, piridiniloksi, fluorofenoksi, izokromanilom, fenolom, benzilamino, -NHCH3, okso-, amino, karboksil, 7-člani spiroaminil, tri do šestero člani cikloalkil, zasićen ili nezasićen i po izboru uključuje jedan ili više heteroatoma odabranih između O i N, i po izboru supstituiran na jednom ili više C ili N atoma s metilom, cijano, fluoro, metilamino, ili trifluorometilom; ili drugi je
A compound of Formula (II), or pharmaceutically acceptable salt thereof: wherein 
Spoj s Formulom (II), ili njegova farmaceutski prihvatljiva sol: pri čemu
is methoxy or cyano, or a compound or pharmaceutically acceptable salt thereof, selected from the group consisting of:- 
je metoksi ili cijano, ili spoj ili njegova farmaceutski prihvatljiva sol, odabran iz skupine koju čine:-
The pharmaceutical composition of claim 12, wherein said compound or pharmaceutically acceptable salt thereof has an IC50 less than or equal to 100 nM against human TLR7 receptors in a HEK-293 cell line. 
Farmaceutski pripravak prema patentnom zahtjevu 12, naznačen time što navedeni spoj ili njegova farmaceutski prihvatljiva sol ima IC50 manji od ili jednak 100 nM protiv ljudskih TLR7 receptora u staničnoj liniji HEK-293.
A method for preparing an immunoglobulin preparation enriched in brain disease-related immunoglobulins, the method comprising the steps: providing a plasma-derived immunoglobulin composition comprising IgG immunoglobulins, the IgG immunoglobulins including an anti-amyloid beta immunoglobulin, an anti-RAGE immunoglobulin, an anti-a-synuclein immunoglobulin, or another immunoglobulin specific to a brain disease-related protein; 
Postupak pripremanja imunoglobulinskog pripravka obogaćenog imunoglobulinima vezanima uz bolest mozga, postupak sadrži korake: pružanje imunoglobulinskog sastava izvedenog iz plazme koji sadrži IgG imunoglobuline, IgG imunoglobulini uključuju anti-amiloid beta imunoglobulin, anti-RAGE imunoglobulin, anti-a-sinuklein imunoglobulin, ili drugi imunoglobulin svojstven za protein vezan uz bolest mozga;
binding the IgG immunoglobulins to a cation exchange material; 
vezanje IgG imunoglobulina na materijal za izmjenu kationa;
eluting a majority of the bound IgG immunoglobulins from the cation exchange material, in a first cation exchange elution step, using a first cation exchange elution buffer having a pH of 4.0 to 10.0 and a conductivity of 3.0 mS/cm to 16.0 mS/cm; 
eluiranje većine vezanih IgG imunoglobulina sa materijala za izmjenu kationa, u prvom eluirajućem koraku izmjene kationa, koristeći eluirajući pufer prve izmjene kationa koji ima pH od 4.0 do 10.0 i vodljivost od 3.0 mS/cm do 16.0 mS/cm;
eluting IgG immunoglobulins remaining bound to the cation exchange material, in a second cation exchange elution step, using a second cation exchange elution buffer having a pH of 4.0 to 10.0 and a conductivity of 10.0 mS/cm to 300.0 mS/cm; and 
eluiranje IgG imunoglobulina koji ostaju vezani na materijal za izmjenu kationa, u drugom eluirajućem koraku izmjene kationa, koristeći eluirajući pufer druge izmjene kationa koji ima pH od 4.0 do 10.0 i vodljivost od 10.0 mS/cm do 300.0 mS/cm; i
The method of claim 1, wherein the plasma-derived immunoglobulin composition provided in step (A) has a higher titer of an anti-amyloid beta immunoglobulin, an anti-RAGE immunoglobulin, an anti-a-synuclein immunoglobulin, or another immunoglobulin specific to a brain disease-related protein, as compared to the titer of a plasma-derived immunoglobulin composition prepared from a plasma pool containing plasma from 1,000 random donors. 
Postupak prema zahtjevu 1, pri čemu imunoglobulinski sastav izveden iz plazme pružen u koraku (A) ima viši titar anti-amiloid beta imunoglobulina, anti-RAGE imunoglobulina, anti-a-sinuklein imunoglobulina, ili drugog imunoglobulina svojstvenog za protein vezan uz bolest mozga, uspoređeno s titrom imunoglobulinskog sastava izvedenog iz plazme pripremljenog iz bazena plazme koji sadrži plazmu od 1,000 nasumičnih donora.
The method according to any of the preceding claims, wherein the cation exchange material is a weak cation exchange material, preferably, a carboxymethyl cation exchange resin. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu je materijal za izmjenu kationa slab materijal za izmjenu kationa, poželjno, karboksimetil smola za izmjenu kationa.
the first cation exchange elution buffer has a conductivity of 4.0 mS/cm to 15.0 mS/cm; or 
eluirajući pufer prve izmjene kationa ima vodljivost od 4.0 mS/cm do 15.0 mS/cm; ili
the first cation exchange elution buffer has a conductivity of 5.0 mS/cm to 8.0 mS/cm. 
eluirajući pufer prve izmjene kationa ima vodljivost od 5.0 mS/cm do 8.0 mS/cm.
The method according to any of the preceding claims, wherein the plasma-derived immunoglobulin composition provided in step (A) is prepared by a method that includes an alcohol precipitation step, wherein the alcohol precipitation step includes formation of precipitate selected from the group consisting of a Fraction I precipitate, a Cohn Fraction II precipitate, a Cohn Fraction II+III precipitate, a Cohn Fraction I+II+III precipitate, a precipitate G, a Kistler-Nitschmann precipitate A, and a Kistler-Nitschmann gamma-globulin precipitate. 
Postupak prema bilo kojem od prethodnih zahtjeva, pri čemu je sastav imunoglobulina izveden iz plazme pružen u koraku (A) pripremljen postupkom koji uključuje korak taloženja alkohola, pri čemu korak taloženja alkohola uključuje formiranje taloga odabranog od skupine koja se sastoji od taloga Frakcije I, taloga Cohn Frakcije II, taloga Cohn Frakcije II+III, taloga Cohn Frakcije I+II+III, taloga G, Kistler-Nitschmann taloga A i Kistler-Nitschmann gama-globulin taloga.
binding immunoglobulin G from the second cation exchange eluate to a second cation exchange material under solution conditions comprising a pH of 4.0 to 10.0 and a conductivity of 1 to 15 mS/cm; 
vezanje imunoglobulina G iz eluata druge izmjene kationa na materijal za drugu izmjenu kationa pod uvjetima otopine koji sadrže pH od 4.0 do 10.0 i vodljivost od 1 do 15 mS/cm;
eluting bound immunoglobulin G from the cation exchange material, in a third cation exchange elution step, using a third cation exchange elution buffer having a pH of 4.0 to 10.0 and a conductivity of 15.0 mS/cm to 300 mS/cm; and recovering a third cation exchange eluate comprising immunoglobulins. 
eluiranje vezanog imunoglobulina G sa materijala izmjene kationa, u trećem eluirajućem koraku izmjene kationa, koristeći eluirajući pufer treće izmjene kationa koji ima pH od 4.0 do 10.0 i vodljivost od 15.0 mS/cm do 300 mS/cm; i
The method according to claim 11, wherein the second cation exchange material is a weak cation exchange resin, preferably, a carboxymethyl cation exchange resin. 
Postupak prema zahtjevu 11, pri čemu je materijal za drugu izmjenu kationa slaba smola za izmjenu kationa, poželjno, karboksimetil smola za izmjenu kationa.
applying immunoglobulin G to an anion exchange column, in an anion exchange flow through step, under solution conditions comprising a pH of 5.0 to 8.0 and a conductivity of 0.5 mS/cm to 5.0 mS/cm; and 
nanošenje imunoglobulina G na kolonu izmjene aniona, u protočnom koraku izmjene aniona, pod uvjetima otopine koji sadrže pH od 5.0 do 8.0 i vodljivost od 0.5 mS/cm do 5.0 mS/cm; i
recovering a flow-through fraction from anion exchange flow-through step (J), the flow-through fraction enriched in anti-amyloid beta immunoglobulins, anti-RAGE immunoglobulins, anti-a-synuclein immunoglobulins, other immunoglobulins specific to a brain disease-related protein, or a combination thereof. 
obnavljanje protočne frakcije iz protočnog koraka izmjene aniona (J), protočna frakcija obogaćena je anti-amiloid beta imunoglobulinima, anti-RAGE imunoglobulinima, anti-a-sinuklein imunoglobulinima, drugim imunoglobulinima svojstvenima za protein vezan uz bolest mozga, ili njihovom kombinacijom.
A brain disease-related immunoglobulin composition enriched in anti-amyloid beta immunoglobulins, anti-RAGE immunoglobulins, anti-a-synuclein immunoglobulins, other immunoglobulins specific to a brain disease-related protein, or a combination thereof, for use in a method for treating a brain disease or disorder, the method comprising, administering a therapeutically effective amount of the brain disease-related immunoglobulin composition to a subject in need thereof, wherein the brain disease related immunoglobulin composition is prepared by a method according to any one of claims 1, 2, 4 to 13 and 15 to 17; and wherein the brain disease or disorder is selected from the group consisting of Alzheimer's disease, Parkinson's disease, transmissible spongiform encephalopathy, Huntington's disease, a prolactinoma, dialysis related amyloidosis, cerebral amyloid angiopathy, Pick's disease, and Icelandic-type Cerebral amyloid angiopathy. 
Sastav imunoglobulina vezanog uz bolest mozga obogaćen anti-amiloid beta imunoglobulinima, anti-RAGE imunoglobulinima, anti-a-sinuklein imunoglobulinima, drugim imunoglobulinima svojstvenima za protein vezan uz bolest mozga, ili njihovom kombinacijom, za uporabu u postupku liječenja bolesti ili poremećaja mozga, postupak sadrži, primjenu terapeutski učinkovite doze sastava imunoglobulina vezanog uz bolest mozga kod subjekta kojemu je to potrebno, pri čemu je sastav imunoglobulina vezanog uz bolest mozga pripremljen postupkom prema bilo kojem od zahtjeva 1, 2, 4 do 13 i 15 do 17; i pri čemu je bolest ili poremećaj mozga odabrana od skupine koja se sastoji od Alzheimerove bolesti, Parkinsonove bolesti, transmisivne spongiformne encefalopatije, Huntingtonove bolesti, prolaktinoma, amiloidoze vezane uz dijalizu, cerebralne amiloidne angiopatije, Pickove bolesti, i cerebralne amiloidne angiopatije islandskog tipa.
An immunoglobulin composition enriched in brain disease-related immunoglobulins, the immunoglobulin composition prepared by a method according to any one of claims 1, 2, 4 to 13 and 15 to 17, wherein the composition comprises an anti-brain disease-related protein immunoglobulin G at a titre that is at least 3-fold greater than the titer of the anti-brain disease-related protein immunoglobulin G in a total IgG composition prepared from the blood/plasma of more than a thousand random individuals. 
Imunoglobulinski sastav obogaćen imunoglobulinima vezanima uz bolest mozga, imunoglobulinski sastav pripremljen je postupkom prema bilo kojem od zahtjeva 1, 2, 4 do 13 i 15 do 17, pri čemu sastav sadrži protein imunoglobulina G vezanog uz anti-moždanu bolest pri titru koji je barem tri puta veći od titra proteina imunoglobulina G vezanog uz anti-moždanu bolest u ukupnom IgG sastavu pripremljenom iz krvi/plazme više od tisuću nasumičnih pojedinaca.
An immunoglobulin composition enriched in infectious disease-related immunoglobulins, the immunoglobulin composition prepared by a method according to any one of claims 3 to 12 and 14 to 16, wherein the composition comprises an anti-infectious disease-related agent immunoglobulin G at a titre that is at least 3-fold greater than the titer of the anti-infectious disease-related agent immunoglobulin G in a total IgG composition prepared from the blood/plasma of more than a thousand random individuals. 
Imunoglobulinski sastav obogaćen imunoglobulinima vezanima uz zaraznu bolest, imunoglobulinski sastav pripremljen postupkom prema bilo kojem od zahtjeva 3 do 12 i 14 do 16, pri čemu sastav sadrži agens imunoglobulina G vezanog uz anti-zaraznu bolest pri titru koji je barem tri puta veći od titra agensa imunoglobulina G vezanog uz anti-zaraznu bolest u ukupnom IgG sastavu pripremljenom iz krvi/plazme više od tisuću nasumičnih pojedinaca.
and R25 are taken together with the nitrogen to which they are attached to form a 4- to 7-membered monocyclic heterocycloalkyl group, or a 6- to 10- membered bicyclic heterocyclic group having fused, spiro, or bridged rings, and each R24 and R25 can be optionally substituted; 
i R25 se uzimaju zajedno sa azotom za koji su vezane, kako bi obrazovale monocikličnu heterocikloalkil grupu sa 4 do 7 članova, ili bicikličnu heterocikličnu grupu sa 6 do 10 članova koja ima kondenzirane, spiro, ili premošćene prstenove, i svaka R24 i R25 grupa može biti izborno supstituirana;
The multilayer film, according to one of the above-mentioned claims, is characterised in that at least one layer contains mixture of copolymer of polypropylene with ethylene and terpolymer of propylene with ethylene and butene where the mole percentage of propylene ranges from 50 to 99 %. 
Višeslojni film, u skladu s jednim od gore navedenih zahtjeva, naznačen time da najmanje jedan sloj sadrži smjesu kopolimera polipropilena s etilenom i terpolimera propilena s etilenom i butenom gdje se molni postotak propilena kreće u rasponu od 50 do 99%.
The multilayer film, according to one of the above-mentioned claims, is characterised in that one of the outer layers comprises mixture of 40-99 % of plastomer being a-olefin copolymer of ethylene (where a-olefin may be butene, hexene, octene) with specific density ranging from 0.860 to 0.910 g/cm3 (preferably 0.880-0.905 g/cm3) and the mass flow rate ranging from 0.5 to 10 g/10 min. 
Višeslojni film, prema jednom od gore navedenih zahtjeva, naznačen time da jedan od vanjskih slojeva sadrži smjesu od 40-99% plastomera koji je a-olefinski kopolimer etilena (gdje a-olefin može biti buten, heksen, okten) specifične gustoće u rasponu od 0,860 do 0,910 g/cm3(poželjno 0.880-0.905 g/cm3) i masenog protoka u rasponu od 0,5 do 10 g/10min.
The multilayer film, according to one of the above-mentioned claims, is characterised in that the blocks of microlayers consist of at least 10 alternate thin layers with the thickness of less than 0.2 µm each microlayer. 
Višeslojni film, u skladu s jednim od gore navedenih zahtjeva, naznačen time da se blokovi mikroslojeva sastoje od najmanje 10 naizmjeničnih tankih slojeva debljine manje od 0,2 µm po mikrosloju.
The method for producing the multilayer film, according to claim 11, is characterised in that at least 1 layer of the film extruded with the use of the slit head contains mixture of copolymer of polypropylene with ethylene and copolymer of polypropylene with a-olefin such as butene, hexene or octene, with the propylene percentage ranging from 50 to 99 %. 
Postupak za proizvodnju višeslojnog filma prema zahtjevu 11, naznačen time da najmanje 1 sloj filma ekstrudiran upotrebom proreza glave sadrži smjesu kopolimera polipropilena s etilenom i kopolimera polipropilena s a-olefinom, poput butena, heksena ili oktena, s postotkom propilena u rasponu od 50 do 99%.
The method for producing the multilayer film, according to one of claims 11-14, is characterised in that to the extruder, from which the material used to produce at least one of the outer layers comes, the following is added: mixture of a-olefin copolymer of linear ultra low-density polyethylene (ULDPE) (where a-olefin may be hexene, octene) with specific density ranging from 0.880 to 0.910 g/cm3 (preferably 0.9-0.91 g/cm3) and mass flow rate ranging from 0.5 to 10 g/10 min. 
Postupak za proizvodnju višeslojnog filma prema jednom od zahtjeva 11-14, naznačen time da se ekstruderu, iz kojeg dolazi materijal koji se koristi za proizvodnju barem jednog od vanjskih slojeva, dodaje sljedeće: smjesa a-olefinskog kopolimera linearnog polietilena ultra niske gustoće (ULDPE) (gdje a-olefin može biti heksen, okten) specifične gustoće u rasponu od 0.880 do 0.910 g/cm3(poželjno 0,9-0,91 g/cm3) i masenog protoka u rasponu od 0,5 do 10 g/10min.
The method for producing multilayer film, according to claims 11-17, is characterised in that the polypropylene or elastomer that comes from a materially recycled raw material is added to at least one intermediate layer. 
Postupak za proizvodnju višeslojnog filma prema zahtjevu 17, naznačen time da se polipropilen ili elastomer koji potječe iz materijalno reciklirane sirovine dodaje barem jednom međusloju.
Sliding gate valve plate (1) for a molten metal gate valve having 
Ploča kliznog ventila (1) za klizna vrata za rastaljeni metal koja ima
a lower surface (3), separated from the upper surface by a thickness of the sliding gate valve plate, said upper and lower surfaces being planar and parallel to one another, 
donju površinu (3), odvojena od gornje površine debljinom ploče kliznog ventila, pri čemu su gornja i donja površina ravne i međusobno paralelne,
a connecting outer surface (4) connecting the upper surface (2) to the lower surface (3) and 
spojnu vanjsku površinu (4) koja povezuje gornju površinu (2) s donjom površinom (3) i